OCT 26, 2016 07:30 PM PDT

Uniting the Two Arms of the Immune System to Fight Cancer

WRITTEN BY: Kara Marker
The newest effort in cancer treatment research involves the combination of not one, not two, not three, but four different cancer immunotherapies to kill tumor cells. So far in mice studies with extremely aggressive cancer, the combination treatment has been 75 percent effective.
T cells are key to the adaptive immune response. In this image, the top row shows few T cells in untreated mice, while the bottom rows show many T cells produced after immunotherapy treatment. Credit: MIT
Two scientists from the Massachusetts Institute of Technology (MIT) have brought their research together to make a cancer therapy juggernaut. First, MIT’s Dane Wittrup, PhD, studied the deliverance of antibodies and a signaling molecule called interleukin-2 (IL-2) that enhances the immune response in mice. The treatment stopped the growth of aggressive melanoma tumors in mice for as long as they received treatment. Plus, Wittrup’s findings appeared to be even more successfully when the researchers added T cells to be delivered along with antibodies and IL-2, stimulating the adaptive immune system.

Then, MIT’s Darrell Irvine, PhD, studied a novel T cell “vaccine” that attaches to lymph nodes via a protein called albumin. Once linked to the lymph nodes, the T cell vaccine stimulates large production of T cells to gang up against the tumor cells.

Once Irvine and Wittrup combined their experimental treatments, they quickly saw both powerhouses of the immune system become activated, the adaptive and the innate responses. Their findings showed that the new therapy has the potential to treat multiple types of human cancer, and it is also possible that the treatment could trigger immune memory so lymphocytes could “remember” the right cancer cells to target and kill if the tumor continues to grow.

"We wondered if we could bring these two [therapies] together and try to generate a more integrated immune response that would bring together all arms of the immune system against the tumor,” Irvine said.


The result of combining the two therapies was a four-part anti-cancer response:
  1. Antibody targeted tumor and recruited additional immune cells to help activate T cells
  2. Vaccine targeted tumor and stimulated the proliferation of T cells to attack the tumor
  3. IL-2 helped the T cell population expand quickly
  4. Anti-PD1 molecule blocked PD1, a receptor found on T cells, so the lymphocytes would stay active longer
They tested the combination treatment in mice implanted with three different types of tumors: melanoma, lymphoma, and breast cancer. These engineered cancers are harder to treat than human tumors implanted in mice because they suppress the immune system.

Overall, no matter what time of tumor the mice were implanted with, the researchers saw a general trend of tumor elimination: just about 75 percent of the tumors were completely destroyed. To confirm the staying power of the treatment, the researchers implanted more tumor cells into the same mice that had cleared their cancer. Their immune systems were once again able to eliminate all of the tumor cells.

"We have shown that with the right combination of signals, the endogenous immune system can routinely overcome large immunosuppressive tumors, which was an unanswered question," said Irvine.

While cancer treatments in the past were often thwarted by the ability of tumor cells to secrete chemicals to remain invisible to the immune system, scientists are hoping to get the immune cells back online with the new combination treatment from MIT.

"To our knowledge, nobody has been able to take tumors that big and cure them with a therapy consisting entirely of injecting biomolecular drugs instead of transplanting T cells," Wittrup said.


In the future, Wittrup, Irvine, and others from MIT plan on designing the combination treatment to treat both specific cases of cancer and broad cases of cancerous growth. Their current study was published in the journal Nature Medicine.
 


Source: Massachusetts Institute of Technology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 17, 2018
Immunology
JUL 17, 2018
Powering up the Elderly's Immune System
Use of drugs that inhibit the TORC1 pathway has bolstered the immune systems of the elderly, leading to a decrease in potentially deadly infections such as pneumonia and influenza....
AUG 06, 2018
Immunology
AUG 06, 2018
Maternal Dengue Immunity Protects Against Infant Zika Infection
Maternal Dengue immunity produces CD8+ T cells that protect against fetal Zika infection preventing zika-related malformations....
SEP 26, 2018
Immunology
SEP 26, 2018
Is Good Bacteria Still Good?
A team of researchers looks at the effects of probiotics on the guts ability to reconstitute a microbiome after antibiotic treatment....
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 08, 2018
Immunology
OCT 08, 2018
Nuclear Imaging: The Next Generation of Biopsy
A team of researchers has published their work in the Journal of Nuclear Medicine describing techniques with PET imaging as an alternative to biopsy methods....
OCT 22, 2018
Immunology
OCT 22, 2018
Barcoding for Cancer Immunity Genes
Scientists develop a novel technology that allows for protein barcoding to reveal gene function...
Loading Comments...